You are here: Agreements > Letter of Intent > True Nature Signs Letter of Intent to Acquire Third Atlanta Compounder

SITE SEARCH
AGREEMENTS / CONTRACTS
(optional)
(optional)
Try our advanced search >>
CLAUSES Search Contract Clauses >>
Browse Contract Clause Library>>

True Nature Signs Letter Of Intent To Acquire Third Atlanta Compounder

Letter of Intent

Legal Documents
You are currently viewing:

 This Letter of Intent involves

TRUE NATURE HOLDING, INC. | True Nature Holding, Inc

. RealDealDocs™ contains millions of easily searchable legal documents and clauses from top law firms. Search for free - click here.
 

Title: True Nature Signs Letter of Intent to Acquire Third Atlanta Compounder
Date: 6/6/2016
Industry: Software and Programming     Sector: Technology

join now
50 of the Top 250 law firms use our Products every day

 

Exhibit 99.1

True Nature Signs Letter of Intent to Acquire Third Atlanta Compounder

 

Innovation Compounding’s Founder Is Slated For Board Role, COO Slot

  

MAY 23, 2016 - Atlanta, Georgia - True Nature Holding, Inc. (OTCQB:TNTY, “the Company”) today announced that it has entered into a letter of intent for the acquisition of Innovation Compounding, based in Kennesaw, Georgia, a suburb of Atlanta. Dr. Shawn Hodges, founder of Innovation, has been offered the position of Chief Operating Officer and a position on the Board of Directors of the Company, subject to approval.

 

Innovation Compounding is a compounding pharmacy that supports over 1,400 prescribers, 17,000 patients and 43,000 prescriptions annually. Their product specialties include men’s and women’s health, pain management, weight loss management, allergy treatments and nutritional therapy. Their corporate web site is: http://innovationcompounding.com

 

Dr. Hodges graduated with a Doctorate in Pharmacy from Texas Tech University School of Pharmacy in 2001. Upon graduation, he was awarded a one-year fellowship program with Eli Lilly where he researched the drug approval process by serving as a regulatory liaison between FDA and Lilly. “We see Dr. Hodges playing a key role in our growth plans in both operations, and product development. His insight and market knowledge has led to a large and growing product set, which we believe will create increased revenues as we move toward a national marketing presence from the current regional emphasis,” said Steve Keaveney, CEO of True Nature.

 

“The consolidation of the compounding marketplace will create profitable opportunities for those well capitalized companies who can acquire the product sales that had previously gone to the smaller operators. With an emphasis on quality, well qualified staff and custom


continue to document